Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

C. Ma, L. Guizzetti, R. Panaccione, R. N. Fedorak, Rish Pai, C. E. Parker, T. M. Nguyen, R. Khanna, N. Vande Casteele, G. D'Haens, W. J. Sandborn, B. G. Feagan, V. Jairath

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background: Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims: To meta-analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials (RCTs) and identify factors influencing these rates. Methods: MEDLINE, EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo-controlled trials of pharmacological interventions for UC. Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta-regression was used to evaluate the influence of patient, intervention and trial-related study-level covariates on these rates. Results: Fifty-six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval (CI) 19-28%] and 35% [95% CI 27-42%] respectively, and 20% [95% CI 16-24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8-22%] for induction trials. High heterogeneity was observed for all outcomes (I2 56.2%-88.3%). On multivariable meta-regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29-0.92], P = 0.03). On univariable meta-regression, higher histologic placebo remission was associated with concomitant corticosteroids (OR = 1.17 [95% CI 1.08-1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions: Placebo endoscopic and histologic rates range from 14% to 35% in UC RCTs but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.

Original languageEnglish (US)
Pages (from-to)1578-1596
Number of pages19
JournalAlimentary Pharmacology and Therapeutics
Volume47
Issue number12
DOIs
StatePublished - Jun 1 2018

Fingerprint

Ulcerative Colitis
Meta-Analysis
Placebos
Maintenance
Confidence Intervals
Adrenal Cortex Hormones
Randomized Controlled Trials
Essential Drugs
MEDLINE
Endoscopy
Libraries
Reading
Pharmacology

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Systematic review with meta-analysis : endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. / Ma, C.; Guizzetti, L.; Panaccione, R.; Fedorak, R. N.; Pai, Rish; Parker, C. E.; Nguyen, T. M.; Khanna, R.; Vande Casteele, N.; D'Haens, G.; Sandborn, W. J.; Feagan, B. G.; Jairath, V.

In: Alimentary Pharmacology and Therapeutics, Vol. 47, No. 12, 01.06.2018, p. 1578-1596.

Research output: Contribution to journalReview article

Ma, C, Guizzetti, L, Panaccione, R, Fedorak, RN, Pai, R, Parker, CE, Nguyen, TM, Khanna, R, Vande Casteele, N, D'Haens, G, Sandborn, WJ, Feagan, BG & Jairath, V 2018, 'Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis', Alimentary Pharmacology and Therapeutics, vol. 47, no. 12, pp. 1578-1596. https://doi.org/10.1111/apt.14672
Ma, C. ; Guizzetti, L. ; Panaccione, R. ; Fedorak, R. N. ; Pai, Rish ; Parker, C. E. ; Nguyen, T. M. ; Khanna, R. ; Vande Casteele, N. ; D'Haens, G. ; Sandborn, W. J. ; Feagan, B. G. ; Jairath, V. / Systematic review with meta-analysis : endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. In: Alimentary Pharmacology and Therapeutics. 2018 ; Vol. 47, No. 12. pp. 1578-1596.
@article{a9d6bf37c7be4052825a69db42d758f5,
title = "Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis",
abstract = "Background: Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims: To meta-analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials (RCTs) and identify factors influencing these rates. Methods: MEDLINE, EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo-controlled trials of pharmacological interventions for UC. Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta-regression was used to evaluate the influence of patient, intervention and trial-related study-level covariates on these rates. Results: Fifty-six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23{\%} [95 confidence interval (CI) 19-28{\%}] and 35{\%} [95{\%} CI 27-42{\%}] respectively, and 20{\%} [95{\%} CI 16-24{\%}] for maintenance of remission. The pooled histologic placebo remission rate was 14{\%} [95{\%} CI 8-22{\%}] for induction trials. High heterogeneity was observed for all outcomes (I2 56.2{\%}-88.3{\%}). On multivariable meta-regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16{\%} vs 25{\%}; OR = 0.52, [95{\%} CI 0.29-0.92], P = 0.03). On univariable meta-regression, higher histologic placebo remission was associated with concomitant corticosteroids (OR = 1.17 [95{\%} CI 1.08-1.26], P < 0.0001, per 10{\%} increase in corticosteroid use). Conclusions: Placebo endoscopic and histologic rates range from 14{\%} to 35{\%} in UC RCTs but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.",
author = "C. Ma and L. Guizzetti and R. Panaccione and Fedorak, {R. N.} and Rish Pai and Parker, {C. E.} and Nguyen, {T. M.} and R. Khanna and {Vande Casteele}, N. and G. D'Haens and Sandborn, {W. J.} and Feagan, {B. G.} and V. Jairath",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/apt.14672",
language = "English (US)",
volume = "47",
pages = "1578--1596",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Systematic review with meta-analysis

T2 - endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

AU - Ma, C.

AU - Guizzetti, L.

AU - Panaccione, R.

AU - Fedorak, R. N.

AU - Pai, Rish

AU - Parker, C. E.

AU - Nguyen, T. M.

AU - Khanna, R.

AU - Vande Casteele, N.

AU - D'Haens, G.

AU - Sandborn, W. J.

AU - Feagan, B. G.

AU - Jairath, V.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims: To meta-analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials (RCTs) and identify factors influencing these rates. Methods: MEDLINE, EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo-controlled trials of pharmacological interventions for UC. Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta-regression was used to evaluate the influence of patient, intervention and trial-related study-level covariates on these rates. Results: Fifty-six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval (CI) 19-28%] and 35% [95% CI 27-42%] respectively, and 20% [95% CI 16-24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8-22%] for induction trials. High heterogeneity was observed for all outcomes (I2 56.2%-88.3%). On multivariable meta-regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29-0.92], P = 0.03). On univariable meta-regression, higher histologic placebo remission was associated with concomitant corticosteroids (OR = 1.17 [95% CI 1.08-1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions: Placebo endoscopic and histologic rates range from 14% to 35% in UC RCTs but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.

AB - Background: Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims: To meta-analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials (RCTs) and identify factors influencing these rates. Methods: MEDLINE, EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo-controlled trials of pharmacological interventions for UC. Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta-regression was used to evaluate the influence of patient, intervention and trial-related study-level covariates on these rates. Results: Fifty-six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval (CI) 19-28%] and 35% [95% CI 27-42%] respectively, and 20% [95% CI 16-24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8-22%] for induction trials. High heterogeneity was observed for all outcomes (I2 56.2%-88.3%). On multivariable meta-regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29-0.92], P = 0.03). On univariable meta-regression, higher histologic placebo remission was associated with concomitant corticosteroids (OR = 1.17 [95% CI 1.08-1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions: Placebo endoscopic and histologic rates range from 14% to 35% in UC RCTs but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.

UR - http://www.scopus.com/inward/record.url?scp=85045911117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045911117&partnerID=8YFLogxK

U2 - 10.1111/apt.14672

DO - 10.1111/apt.14672

M3 - Review article

C2 - 29696670

AN - SCOPUS:85045911117

VL - 47

SP - 1578

EP - 1596

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 12

ER -